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Introduction
Bone tissue engineering (TE) aims to find a better solution for 
the healing of large bone defects and non-unions through creation
of an in vivo microenvironment that promotes local bone repair or
regeneration. Indeed, proof of principle has been delivered, also in
patients, demonstrating that healing of such lesions can be
achieved by seeding cells in a matrix, followed by implantation of
the construct into the defect [1–5]. Yet implantation of TE con-
structs, i.e. cell-scaffold or scaffold-growth factor combination,
falls short of the bone healing obtained by transplantation of autol-
ogous bone grafts, considered as the golden standard [2, 6].
Delayed and non-unions harbour a microenvironment which
fails to support bone repair or regeneration. Hence, this suggests
that the microenvironment found at a non-union defect may be con-
sidered as an ectopic site as little, if any, bone formation occurs.
Based on this rationale, TE constructs should display osteoinductive
properties to promote the bone healing process. Osteoinductive
properties of various biomaterials, osteogenic cells and growth fac-
tors or combinations thereof have been studied in ectopic bone for-
mation models in a wide variety of species, ranging from mouse, rat
and rabbit to dog, sheep and goat [7–11]. A popular model, in par-
ticular when using allogeneic or xenogeneic cells, is the nude mouse
model in which TE constructs are implanted subcutaneously in the
back of athymic mice [12–17]. The advantages of this model are (i)
that no immunosuppressant agents, that may affect the osteogenic
process need to be administered [18, 19] and (ii ) that most bioma-
terials rarely induce bone in rodents, allowing better evaluation of an
engineered implant [20].
When assessing cell seeded implants, the amount of bone
formed is not only dependent on the specific physicochemical prop-
erties of the scaffold material [8, 21], but also on the tissue source
of the cells [22], animal species [7, 9] and genetic modification of
the cells [23–26] Hence, in this model, successful ectopic bone
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In this study, we investigated a clinically relevant model of in vivo ectopic bone formation utilizing human periosteum derived cells
(HPDCs) seeded in a CollagraftTM carrier and explored the mechanisms by which this process is driven. Bone formation occurred after
eight weeks when a minimum of one million HPDCs was loaded on CollagraftTM carriers and implanted subcutaneously in NMRI nu/nu
mice. De novo bone matrix, mainly secreted by the HPDCs, was found juxta-proximal of the calcium phosphate (CaP) granules suggest-
ing that CaP may have triggered the ‘osteoinductive program’. Indeed, removal of the CaP granules by ethylenediaminetetraacetic acid
decalcification prior to cell seeding and implantation resulted in loss of bone formation. In addition, inhibition of endogenous bone mor-
phogenetic protein and Wnt signalling by overexpression of the secreted antagonists Noggin and Frzb, respectively, also abrogated
osteoinduction. Proliferation of the engrafted HPDCs was strongly reduced in the decalcified scaffolds or when seeded with adenovirus-
Noggin/Frzb transduced HPDCs indicating that cell division of the engrafted HPDCs is required for the direct bone formation cascade.
These data suggest that this model of bone formation is similar to that observed during physiological intramembranous bone develop-
ment and may be of importance when investigating tissue engineering strategies.
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formation requires a cell-material combination wherein the material
supports the initiation and progression of the bone formation pro-
gram of the engrafted cell type. Although material characteristics
such as macro-/micro-porosity and surface topography have been
identified to modulate osteoinduction [27–29], the mechanism of
action of ectopic bone formation obtained by a cell based implant is
still largely unknown. Conversely, understanding the mechanism of
action is a prerequisite to the design and optimization of the engi-
neering process for clinically relevant tissue constructs.
In this study we describe the importance of bone morpho-
genetic protein (BMP) and Wingless (Wnt) signalling in human
periosteum derived cells (HPDCs) during osteoinduction on cal-
cium phosphate (CaP) carriers. We investigated the use of perios-
teum derived cells, rather than bone marrow mesenchymal stem
cells, as the integrity of this tissue is critical during the fracture
healing process. In addition it has also been shown to be a potent
cell source for bone production, which is due to the presence of
progenitor cells which can contribute to bone growth and devel-
opment [16, 30]. This in vivo study, with clinically relevant cells
and scaffold materials, represents a model system for the further
study of osteoinduction which may lead to the development of
regenerative treatments for the repair of non-union bone defects.
Materials and methods
Harvest of periosteal tissue and isolation 
of the cells
Periosteal biopsies (10 mm  5 mm) were harvested from the medial side
of the proximal tibia of male and female adolescent and adult patients 
(n  15, age 20.7 [S.D. 12.2]) during total knee replacement surgery or
distraction osteogenesis. The periosteum was stripped from the tibia 
with a periosteal lifter. The periosteal specimens were transported in
growth medium consisting of high-glucose Dulbecco’s modified medium
(DMEM, Invitrogen, Merelbeke, Belgium) supplemented with 10% FBS
(BioWhittaker, Verviers, Belgium) and antibiotic–antimycotic solution 
(100 units/ml penicillin, 100 g/ml streptomycin and 0.25 g/ml ampho-
tericin B; Invitrogen). The biopsies were finely minced and digested
overnight at 37C in 0.2% type IV collagenase (Invitrogen) in growth
medium (as described above). Subsequently periosteal cells were collected
by centrifugation and seeded in a T25 flask in growth medium. Non-adher-
ent cells were removed after 5 days by changing the medium. The ethical
committee for Human Medical Research (Katholieke Universiteit Leuven)
approved all procedures, and patient informed consent form was obtained.
Cell culture
Cells were expanded in monolayer in growth medium. Upon confluence,
HPDCs were trypsin released (0.25% trypsin, 1 mM ethylenediaminete-
traacetic acid [EDTA]; Invitrogen) and replated with a seeding density varying
between 7000 and 10,000 cells/cm2. For cryopreservation, HPDCs were sus-
pended in DMEM with 20% FBS and 10% DMSO (Sigma, Bornem, Belgium)
and stored in liquid nitrogen. For the in vivo osteogenic assays cells were
thawed, replated and expanded in T175 flasks (Greiner, Wemmel, Belgium).
Preparation of the scaffolds
CollagraftTM (Neucoll, Inc., Cambell, CA, USA), an open porous composite
made of CaP granules consisting of 65% hydroxyapatite and 35% 
-tri-calcium phosphate (-TCP), embedded in a bovine collagen type I
matrix, was punched into 21 mm3 cylindrical (diameter 3 mm, height 
3 mm) scaffolds. To investigate the role of CaP on bone formation, the con-
centration of CaP in the CaP-collagen matrices was reduced by immersing
the punched CollagraftTM carriers in an EDTA/PBS buffer for 2 weeks.
Control scaffolds were immersed in PBS (vehicle control) or left untreated.
After treatment, the scaffolds were washed twice with PBS followed by
lyophilization to dry the structures.
In vivo osteogenesis
Phenotypically stable periosteum-derived (P3–7) cells [31] were trypsin
released, centrifuged and re-suspended at a concentration of 20 million
cells/ml. Subsequently, the cells were transduced with adenovirus-GFP or
adenovirus-noggin (MOI of 20; obtained from Galapagos, Mechelen,
Belgium) for 20 min. The transduced HPDCs were labelled with CM-DiI
dye (Invitrogen) according to the manufacturer’s instructions. After
labelling the cells were collected, centrifuged and resuspended in 40 l
growth medium which was subsequently applied to the upper surface of
each scaffold. In one experiment the scaffolds were loaded with human
recombinant BMP-2. Two micrograms of human recombinant BMP-2
(hrBMP-2) (CHO expressed, a gift from Genetics Institute, Cambridge,
MA, USA) was diluted in 18 l PBS and applied to the Collagraft™ by
absorption before cell seeding. To allow cell attachment, the seeded scaf-
folds were incubated overnight at 37C. After incubation, the CollagraftTM
was directly implanted subcutaneously in the back at the cervical region
of NMRI-nu/nu mice. The remaining cells in the supernatant were counted
to estimate the seeding efficiency which was calculated as follows: ([num-
ber of seeded cells – number of cells in the supernatant]/number of
seeded cells)  100. Cell viability was assessed by trypan blue exclusion
test. The implants were collected after 1, 2, 4 and 8 weeks of implantation.
Each implant was fixed in 4% formaldehyde, decalcified in EDTA/PBS 
(pH 7.5) for 2 weeks, paraffin embedded and processed for histology. All
procedures on animal experiments were approved by the local ethical
committee for Animal Research (Katholieke Universiteit Leuven). The ani-
mals were housed according to the guidelines of the Animalium Leuven
(Katholieke Universiteit Leuven).
Histomorphological analysis
To quantify ectopic bone formation, histomorphometry was performed in
at least 10 sections per implant as described by Martin et al. [32]
Immunohistochemistry for human and mouse osteocalcin was performed
using a guinea-pig anti-human osteocalcin or a rabbit antimouse osteocal-
cin primary antibody (a gift from Legendo, KULeuven, Leuven, Belgium)
and a peroxidase-conjugated goat anti-guinea or goat anti-rabbit second-
ary antibody (Jackson Immunoresearch Laboratories, De Pinte, Belgium)
diluted 1:100 in PBS and 3,3	-diaminobenzidine (DAB, Sigma) as a chro-
mogenic substrate. The primary antibodies were not cross-reactive to
other species [16]. To visualize phosphorylated Smad proteins a primary
rabbit anti-phospho Smad 1/5/8 (Cell signaling, Bioké, Leiden, The
Netherlands) antibody was used.
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In situ hybridization (ISH) for human 
and mouse Alu repeats
The probes for human specific and mouse specific Alu were prepared by
PCR [12, 33]. ISH was performed as described previously [34]. Briefly,
paraffin sections were deparaffinized in Histoclear™ (Laborimpex,
Brussels, Belgium) and methanol, and rinsed with distilled water.
Subsequently the sections were equilibrated in 0.2 N HCl for 7 min. at
room temperature, incubated in 1.7 mg/ml pepsin in 0.2 N HCl for 10 min.
and washed twice with PBS for 10 min. Sections were acetylated in 0.25%
acetic acid containing 0.1 M triethanolamine (pH 8; Sigma) for 10 min. and
pre-hybridized with 50% deionized formamide containing 4 SSC buffer
(Invitrogen) for 20 min. at 37C. The sections were covered with hybridiza-
tion buffer (1 Denhardt’s solution, 0.2 mg/ml denatured salmon sperm
DNA, 4 SSC, and 50% deionized formamide (all products from Sigma,
unless otherwise stated) containing 1 ng/l digoxigenin-labelled DNA
probe specific for mouse or human Alu genomic repeats. Denaturation of
both genomic DNA of the template and the probe was achieved by heating
the slides at 94C for 1 min. Hybridization was performed overnight at
42C. Thereafter, the slides were washed in 2 and 1 SSC for 1 hr at
room temperature. Digoxigenin was detected using anti-digoxigenin-alka-
line phosphatase conjugated Fab fragments (Roche Diagnostics, Penzberg,
Germany) according to the manufacturer’s recommendations.
Real-time quantitative PCR
Half of each Collagraft™ explant was submerged in lysis buffer from the
Nucleospin RNA-extraction kit (BD Biosciences, Erembodegem, Belgium)
and homogenized. RNA extraction was performed according to manufac-
turer’s instructions. Complementary DNA (cDNA) was obtained by reverse
transcription of 1 g of total RNA with Oligo (dT)20 as primer (Superscript
III; Invitrogen). Taqman PCR was performed on a Rotor-Gene 6000 system
(Corbett, Westburg, Leusden, The Netherlands) using the assay-on-
demand probes from Applied Biosystems. (Assay numbers: hGAPDH:
Hs99999905_m1, hBMP-2: Hs00154192_m1, hBMP-6: Hs00233470_m1,
hID1: Hs00704053_s1, hID2: Hs00747379_m1, hID3: Hs00171409_m1,
hWISP1: Hs00180245_m1, hWISP2: Hs00180242_m1, hAxin2:
Hs01063168_m1, mNoggin: Mm00476456_s1, hFrzb: Hs00173503_m1).
Statistical analysis
Data are expressed as mean  S.D. Statistical significance was determined
using a Mann-Whitney U-test to compare two independent groups, with a
two-sided P-value less than 0.05 being considered as significant.
Results
A minimum number of HPDCs are required 
to induce the bone formation process
To determine if a minimal amount of cells are needed to induce
ectopic bone formation in our model, different quantities of cells
(5  104, 5  105, 1 and 5 million) from three different donors
were seeded in Collagraft™ scaffolds. The seeding efficiency was
more than 95% for all conditions except for the seeding of 5 
106 cells (69% [S.D. 20%]). Eight weeks after implantation, the
implants loaded with 50,000 cells showed very loose connective
tissue (Fig. 1A), which is not different from non-cell seeded
implants [7]. Implants seeded with 500,000 HPDCs were filled
with fibrous tissue, but no bone, whereas 2.2% up to 19.4% 
of bone (BV/TV) was found in implants seeded with one or five
million cells (Fig. 1A, B).
The resulting ectopic bone is a chimeric tissue
and follows a bone formation process similar 
to intramembranous ossification
To investigate the origin of the newly formed bone tissue we per-
formed ISH for human and mouse-specific Alu repeats on consec-
utive sections. Both human and mouse (Fig. 1C) cells were located
in the same bone spicules. These results were confirmed by fluo-
rescent in situ hybridization for Y-chromosome on sections of
Collagraft™ implants loaded with HPDCs from a male donor (data
not shown). Quantification of the Y cells indicated that 71% of
the cells found in the bone spicules were of human origin,
whereas the fibrous tissue contained 40% human cells.
Immunohistochemistry for human and mouse-specific osteocal-
cin (Fig. 1D) confirmed that both cell types contributed actively to
bone matrix deposition.
Histological analysis at different time-points showed that the
ossification process by HPDCs in CollagraftTM occurred without a
cartilage intermediary and appeared similar to bone formed via
intramembranous bone formation. One and 2 weeks after implan-
tation HPDCs migrated into the centre of the implant and prolifer-
ated. Four weeks after implantation, the CaP granules were cov-
ered with a cell layer which started to deposit bone matrix and
bone spicules could be detected 6 and 8 weeks after implantation.
(Fig. 1E) At no time-point, zones of cartilage formation suggestive
for endochondral bone formation were observed. As a control
experiment, hrBMP-2, a growth factor well known for ectopic
induction of an endochondral bone formation cascade [35], was
loaded alone or in combination with one million HPDCs on
Collagraft™ and implanted subcutaneously. Two weeks after
implantation hypertrophic cells embedded in cartilaginous matrix
were detected and 4 weeks later the CollagraftTM implants dis-
played bone ossicles filled with marrow spaces (Fig. 1F) confirm-
ing the osteoinductive properties of BMPs through endochondral
ossification, also in athymic mice.
Hydroxyapatite/-TCP granules are required 
for osteoinduction by HPDCs
As bone spicules were only observed to grow on the CaP granules
of CollagraftTM, we suggested that the mineral granules were
1848 © 2009 The Authors
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Fig. 1 Characterization of the ectopic bone formation model. (A) Haematoxylin and eosin staining of Collagraft™ implants seeded with 50,000 (left),
500,000 (middle) and one million cells (right) 8 weeks after implantation (CB  collagen bundles of the Collagraft™; B  bone, C  Collagraft™; FT 
fibrous tissue, magnification  100, bar  200 m). (B) Quantification of the bone showed that a minimum number of HPDCs had to be seeded
before bone formation occurred (n  6: duplicate implants of three different donor cells). (C) ISH of human (left) and mouse specific Alu repeats (right)
(B  bone, FT  fibrous tissue, magnification: 100; bar  100 m). (D) Immunohistochemical staining for specific human (left) and mouse osteo-
calcin (right). The black arrows depict some positive osteocytes and osteoblasts present in the newly formed bone (haematoxylin counterstained, 
bar  50 m). (E) Toluidine blue staining of Collagraft seeded with HPDCs, displaying a cell layer adjacent to the hydroxyapatite granules 4 weeks after
implantation (left) initiating deposition of de novo bone tissue (right, haematoxylin and eosin staining), a cascade of events similar to membranous bone
formation. To compare this process with endochondral bone formation, 2 g of BMP-2 was loaded on Collagraft™ carriers and seeded with HPDCs. (F)
Metachromatic staining of toluidine blue revealed cartilage matrix 2 weeks after implantation (left). Six weeks after implantation, cartilage matrix was
replaced by bone tissue and bone marrow (right, haematoxylin and eosin staining) (B  bone; Ma  bone marrow, C  Collagraft™; Cg  Cartilage,
magnification  100, bar  200 m).
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important for the induction of the bone formation process by
HPDCs. To address this hypothesis, CollagraftTM scaffolds were
decalcified prior to seeding and implantation. No bone or fibrous
tissue was found 8 weeks after implantation (Fig. 2A).
Interestingly, some areas in these implants appeared to have
higher cell density and an increased tissue density as indicated by
haematoxylin and eosin staining (Fig. 2A inset). In these areas,
remnants of mineral granules were located which were appar-
ently/possibly not removed by the decalcification procedure 
(Fig. 2B) and contained higher concentrations of cells labelled with
cell tracking dye, indicating the presence of the HPDCs (Fig. 2B’).
Scanning electron microscopy and energy dispersive X-ray analy-
sis confirmed the presence of CaP granule remnants (Fig. 2C
inset) serving as anchoring points for cell attachment. (Fig. 2C)
These findings suggest that CaP needs to be present in sufficient
quantities or in a specific composition to induce and/or maintain
the ectopic ossification process by HPDCs.
BMP and Wnt signalling are involved in ectopic
bone formation by HPDCs
The original discovery of BMPs as osteoinductive factors
prompted us to study BMP expression levels in vivo [35, 36]. 
In vivo, transcripts of hBMP-2, -4, -6 and -7 increase over time,
during progression of the bone formation process. (Fig. 3A) BMP-9
mRNA expression was not detected. Immunohistochemistry for 
p-Smad 1/5/8 revealed positive cells at 1 and 8 weeks (Fig. 3B, D)
indicating that the BMP signalling pathway was active.
To inhibit BMP signalling in our model, HPDCs were trans-
duced with adenovirus noggin prior to implantation in nude mice.
Mouse noggin, undetectable in the controls, was highly expressed
1 week after transduction and implantation (Fig. 3C). Expression
of adenoviral noggin progressively decreased at 4 and 8 weeks,
but remained elevated as compared to GFP transduced controls.
This was confirmed by immunohistochemistry for noggin at the
respective time-points. (Data not shown) To evaluate whether
noggin affected BMP signalling, we performed immunohisto-
chemistry for p-Smad 1/5/8. One week after implantation a signif-
icant amount of ad-GFP transduced HPDCs stained positive 
(Fig. 3D), whereas the number of p-Smad cells in the implants
seeded with ad-noggin HPDCs was dramatically decreased (Fig. 3E).
Eight weeks after implantation, the implants seeded with non-
transduced cells (Fig. 3F–H) or with ad-GFP transduced cells were
filled with equal amounts of de novo bone tissue, while the
implants containing ad-noggin transduced cells showed very 
little or no bone. (P 
 0.05, Mann-Whitney U-test, three donors in
Fig. 2 Loss of bone formation in decalcified Collagraft™ carriers. (A)
Haematoxylin and eosin staining of decalcified Collagraft™ implants seeded
with HPDCs showed no bone spicules 8 weeks after implantation. Some
areas of the sections appeared to be condensed and had a more
eosinophilic appearance (black arrows). A higher magnification is displayed
in the inset (200). (B, B’) Phase contrast and red fluorescent image of a
consecutive section revealed crystalline remnants of mineral granules
associated with the presence of CMDi-I labelled cells (white arrows) 
indicating that HPDCs were still present (DAPI counterstained). (bar 
100 m) (C) Scanning electron microscope image of a remnant granule
serving as an anchoring point for cell attachment (white arrow indicate a
cell attaching to the mineral remnants, magnification 5000, bar  5 m).
(Inset C) Energy dispersive X-ray analysis of the granules (marked with an
asterisk) showing peaks of carbon, oxygen, phosphor and calcium indica-
tive for the presence of organic and CaP constituents (Au: gold peak origi-
nates from sputtered gold layer for high quality imaging).
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Fig. 3 Ectopic bone formation by HPDCs requires endogenous BMP signalling. (A) mRNA expression levels of human BMP-2 and -6 normalized to
hGAPDH at 1, 4 and 8 weeks after implantation (n  3; bar  standard deviation) as measured with real-time PCR. (B) Immunohistochemistry revealed
p-Smad 1/5/8 cells (black arrows; bar  50 m). To block the endogenous BMP signalling HPDCs were transduced with ad-noggin. (C) Gene expression
of mouse noggin normalized to hGAPDH in implants retrieved 1, 4 and 8 weeks after implantation (bar  standard deviation). To evaluate the efficacy
of the noggin treatment, immunohistochemistry for p-Smad 1/5/8 staining was done on 1-week-old implants seeded with ad-GFP (D) or ad-noggin (E)
transduced HPDCs. (Haematoxylin counterstained, 200, bar  50 m.) Eight weeks after implantation, haematoxylin and eosin staining (F, G) and
corresponding auto fluorescence images (F’, G’) of implants seeded with ad-GFP transduced HPDCs (F, F’) and ad-noggin transduced cells (G, G’) 
(bar  1 mm) showed consistent reduction in bone tissue, which was quantified by histomorphometrical analysis (H; bar  standard error; a P 
 0.05,
three donors in duplicate).
duplicate) These data demonstrate that endogenous BMP signalling
is required in this bone formation process. However, in contrast to
the endochondral ossification process induced by BMP ligands,
the bone formation process of HPDCs followed an intramembra-
nous cascade (Fig. 1E, F) suggesting that other pathways may be
involved in regulating intramembranous versus endochondral
bone formation. Wnt signalling has been reported as a major reg-
ulator of osteochondral differentiation of mesenchymal stem cells
during limb development [37, 38]. In this animal model, some
cells displayed nuclear staining for -catenin 2 weeks after
implantation suggestive for activation of -catenin dependent Wnt
signalling (Fig. 4A). To test if endogenous Wnt signalling was
required in the ossification process of HPDCs, Frzb, a Wnt antag-
onist, was overexpressed in the seeded cells prior to implantation.
Protein expression of Frzb by HPDCs in cell lysate and in 
the medium was confirmed by Western blot at different MOIs 
(Fig. 4B). Upon implantation, no fibrous tissue or bone spicules
were found up to 8 weeks (Fig. 4C, D).
Noggin and Frzb down-regulate their respective
target genes in the ectopic bone formation model
To validate if adenoviral transduction with noggin or Frzb specifi-
cally altered downstream BMP or Wnt signalling, gene expression
of noggin and Frzb and BMP/Wnt target genes was measured 
1 week after implantation. Mouse noggin and human Frzb mRNA
were only significantly up-regulated when transduced with ad-
noggin or ad-Frzb respectively (Fig. 5A). Two BMP target genes,
ID1 and ID3, were down-regulated in the implants seeded with ad-
noggin transduced cells whereas ID2 gene expression was not
affected by either (Fig. 5B). Transduction with ad-Frzb resulted in
lower expression of WISP-2 but not WISP-1 or Axin2, two direct
Wnt/-catenin target genes (Fig. 5C). Gene expression of above
mentioned genes was unchanged in HPDCs engrafted in decalcified
Collagraft™ carriers as compared to the controls (data not shown).
(aP  0.05, n  4 different donors, bar  standard error).
Fig. 4 Overexpression of Frzb leads to abro-
gation of bone formation. (A) -catenin
nuclei (black arrows) were detected with
immunohistochemistry 4 weeks after implan-
tation suggesting the involvement of Wnt sig-
nalling in the bone formation process. To
block Wnt signalling, HPDCs were transduced
with ad-Frzb. (B) Western blot analysis for
Frzb on cell lysate and medium of HPDCs
transduced with adenovirus Frzb at different
MOIs (lanes 1–4: cell lysate; lanes 5–8:
medium; non-transduced cells: lanes 1 and 5;
MOI of 10 lanes 2 and 6; MOI of 50: lanes 3
and 7; MOI of 100: lanes 4 and 8). Based on
the Western blot, an MOI of 100 was consid-
ered as being most efficient and was applied
for the in vivo study. (C, D) Haematoxylin and
eosin staining and corresponding red fluores-
cent images of implants seeded with ad-GFP
(C) or ad-Frzb (D).
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Depletion of CaP and reduction of BMP 
or Wnt signalling leads to impaired proliferation
of HPDCs
When interfering with the bone formation process, be it by decal-
cification or abrogation of the BMP/Wnt signalling pathway, it was
striking that fewer cells were present in the implants as compared
to the controls. Many cells were positive for CMDi-I, and neither
caspase 3 nor TUNEL staining revealed significant apoptosis at
earlier time-points (data not shown). Therefore we suggested that
proliferation was impaired. Indeed, quantification of human-
specific Ki67 cells (Fig. 6A, bar  100 m) showed reduced
numbers of proliferating HPDCs 2 weeks after implantation when
BMP or Wnt signalling was inhibited (Fig. 6B) or when CaP 
granules were dissolved (Fig. 6C, EDTA condition). Collagraft™
scaffolds soaked in PBS for 2 weeks were used as vehicle control
(Fig. 6C, PBS condition).
Discussion
The production of TE bone substitutes is of great clinical impor-
tance to allow the treatment of non-union bone defects. The cur-
rent surgical ‘gold standard’ for therapy of this type of condition is
the iliac crest autologous graft. Although this technique is the
standard for non-unions there are multiple complications associ-
ated with it [39–41]. To create a functional bone substitute to
replace grafting it would need to mimic the properties of autolo-
gous bone. The model described within provides a platform to
investigate the osteoinduction process using clinically relevant
cells and scaffold materials.
Our data suggest that the osteoinduction displayed by HPDCs
in CollagraftTM can be considered as a semi-autonomous (self-
regulating) process producing bone spicules similar to that of
intramembranous ossification. A minimal amount of one million
(40,000 to 50,000 cells/mm3) cells were required to initiate osteo-
genesis whereas carriers seeded with fewer cells did not display
any bone formation within an 8-week time span. Similar threshold
dynamics in this model has been reported for human bone mar-
row derived cells [12, 42]. CollagraftTM by itself could not trigger
the host cells to deposit bone at the site of implantation. In addi-
tion, implantation of HPDC seeded CollagraftTM carriers in sub-
lethally irradiated mice to reduce proliferation of the host cells
does not alter the bone formation process (data not shown), sug-
gesting that direct contribution of the mouse environment to the
onset of the ectopic bone formation process was limited.
Additional evidence, such as the lack of bone formation by HPDCs
in CollagraftTM implants seeded with human dermal fibroblasts
[16] or myoblasts [43] further illustrates the importance of
cell/material interactions in TE constructs to induce ectopic bone
formation. However, host cells did contribute to bone formation at
8 weeks after implantation. These data suggest that while TE
implants induce the process of bone formation it may be subse-
quently remodelled by host cells.
The mechanism by which a biomaterial such as Collagraft™
contributes to the process of osteoinduction with HPDCs is cur-
rently not clear. There is, however, a growing paradigm that only
CaP containing biomaterials or biomaterials on which a CaP layer
precipitates after implantation have the potential to induce
Fig. 5 Gene expression of BMP and Wnt target genes in vivo. (A) Gene
expression of mouse noggin and human Frzb, (B) BMP target genes (ID1,
ID2 and ID3) and (C) Wnt target genes (Axin2, WISP1 and WISP2) in
implants seeded ad-GFP (GFP), ad-noggin (Noggin) or ad-Frzb (Frzb)
transduced HPDCs 1 week after implantation (GOI: gene of interest; 
n  4 different donors, bar  standard error of the mean, aP  0.05: 
significantly different between test condition and control group).
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ectopic bone formation in vivo [28]. Also in our experiments,
depletion of CaP resulted in loss of bone formation. Even though
HPDCs were still present in the scaffolds 8 weeks after implanta-
tion, the residual collagen type I matrix did not initiate osteoin-
duction. Downstream mechanisms of CaP initiating the process
of osteoinduction remain to be elucidated. There are, however,
various studies which report the induction of osteogenic genes in
various mineralizing cells in vitro in response to calcium and
phosphate. For example, extracellular phosphate has been shown
to affect the expression profile of osteogenic related genes in
cementoblasts. Osteopontin transcription was shown to increase
in relation to phosphate; however, bone sialoprotein has been
shown to decrease [44]. Interestingly phosphate has recently
been reported to act on the osteopontin promoter, through the
glucocorticoid receptor, as observed with dexamethasone medi-
ated osteogenesis [45]. In addition microarray studies with
cementoblasts stimulated with phosphate have shown altered
gene transcription for a wide variety of genes including those
involved in cell signalling, namely in the Wnt and BMP pathways
[46]. In addition to this, extracellular calcium has previously been
shown to increase the expression of BMP-2, -4 and collagen type
I in bone cells [47]. Although these results are in vitro, several
groups have suggested that BMP signalling is involved in vivo,
but no compelling evidence was presented [28, 48–50]. To
address this issue, endogenous BMP signalling was abrogated
through adenoviral overexpression of Noggin, therefore blocking
BMP-2, -4 and -7 signalling [51, 52]. Bone formation was
strongly reduced in all implants seeded with ad-Noggin trans-
duced HPDCs demonstrating that BMP signalling is essential for
Collagraft™/HPDC driven ectopic bone formation. Interestingly,
when BMP ligands were loaded on the CaP carriers together with
HPDCs, endochondral bone formation was observed, suggesting
that BMP signalling is involved in both intramembranous and
endochondral bone formation. To investigate whether HPDCs
could be engineered to predispose them to endochondral bone
formation, Wnt signalling was modulated in our model, as this
signalling pathway has been reported to control the osteochon-
drogenic differentiation of progenitor cells during limb develop-
ment [37]. Indeed, overexpression of ad-Frzb blocked bone for-
mation in our implants, but did not change cell fate of the
periosteal cells into the chondrogenic lineage. This could be
explained by the mechanism through which Frzb interferes with
Wnt signalling. Similar to Noggin, in BMP signalling, Frzb binds
to Wnt ligands, therefore preventing ligand–receptor interaction
[53–55]. As a consequence, downstream Wnt signalling cannot
be initiated or maintained as soluble ligands are captured by Frzb
before receptor binding. Currently, Frzb is known to bind to Wnt1,
Wnt3A and (Xenopus)Wnt8, but it only impairs Wnt1- and Wnt8-
induced -catenin dependent Wnt signalling [54, 56].
Alternatively, Frzb can also bind to epidermal growth factor (EGF)
and antagonize EGF-induced changes in intracellular calcium
homeostasis [57].
Interestingly, the gene expression profile of axin 2 and WISP-1
(Wnt1-induced signalling pathway protein 1), two target genes of
-catenin, was not reduced as a result of Frzb overexpression
Fig. 6 Proliferation of HPDCs in Collagraft™ is affected by noggin, 
frzb and when CaP granules are removed. (A) Immunohistochemistry for
human specific Ki67 to detect proliferating HPDCs (black arrows) 
2 weeks after implantation (haematoxylin counterstained, bar  100 m).
(B and C) Box plots representing the quantification of Ki67 cells in at
least 10 sections per implant (n  3) (bars represent S.D.; a P  0.05:
test group versus control).
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(Fig. 6) suggesting perhaps only a partial modulation of this path-
way. However, expression of WISP2, another member belonging
to the connective tissue growth factor family, was affected by Frzb
but not by noggin demonstrating a specific cell response to Frzb.
Overexpression of Frzb also resulted in a significant reduction of
proliferating HPDCs, a finding which was also observed when
noggin was overexpressed or when CaP was removed. These data
correspond to the current knowledge of BMP and Wnt signalling
related to the regulation of cell proliferation during embryonic
development and cancer [58–62]. In our model, the proliferation
process was perhaps not restricted to putative bone forming cells
as bone formation in this model was associated with the formation
of a fibrous compartment. (Fig. 1) Low cell density (2000–
3000 cells/mm3) was not sufficient to generate fibrous tissue.
However, when this number was increased to half a million cells
seeded, a fibrous compartment was formed 8 weeks after implan-
tation suggesting a possible delay of the process. This finding
suggests that this fibrous area may serve as a stromal compart-
ment required to start differentiation of the cells adjacent to the
bone spicules. Indeed, Liu et al. recently reported that implanted
bone marrow derived cells overexpressing Wnt1 develop a fibrous
compartment and stimulate osteogenic differentiation of the
Wnt1– cells residing juxta-proximal of the CaP granules, therefore
further supporting this hypothesis [63]. Alternatively, the fibrous
tissue could be the result of a rapid proliferating fibroblast sub-
population either derived from the in vitro expanded HPDCs either
infiltrated from the host environment.
Osteoinduction by HPDCs in a Collagraft™ matrix ectopically in
the nude mouse is a clinically relevant in vivo model which can be
used to study the initial events of bone formation for TE purposes.
The validity of this process has been verified by modulation of both
the Wnt and BMP signalling pathways which results in a reduction
in bone formation. In addition, this model can be regarded as a
semi-autonomous process wherein proliferation of the engrafted
cells is an essential module of osteoinduction. We provide evidence
that CaP is essential for proliferation and differentiation of HPDCs
into bone forming cells and in combination with other reported
studies this is likely to be due to the induction of bone specific tran-
scripts. Further study on the exact role of calcium and phosphate
on the osteogenic process with HPDCs in vivo may provide further
insight to bone repair and lead to novel TE bone therapeutics.
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